Lachlan joined Oxford Sciences Innovation in 2015 as a member of the founding team. Whilst there, he made investments at the intersection of technology and biology including foundational seed investments in OMass Therapeutics, ONI, Spybiotech, Nucleome and Base Genomics which was acquired by Exact Sciences in 2020 for $410m. In 2020 he left to found his own company and joined the board of Depixus as part of the Series A.